FDA Drug recall D-0223-2018
Simvastatin Tablets, USP, 40 mg, 1000-count bottle, Rx only, Manufactured for: Camber Pharmaceuticals, Inc., Piscataway, NJ 08854, Manufact…
- FDA Drug
- Class III
- terminated
- Published 2018-01-24
On 2018-01-24 the FDA classified a Class III recall of Simvastatin Tablets, USP, 40 mg, 1000-count bottle, Rx only, Manufactured for: Camber Pharmaceuticals, Inc., Piscataway, NJ 08854, Manufact… by Hetero Labs Unit Iii, citing presence of foreign substance: metallic razor blade was found in one bottle.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0223-2018 |
| Classification | Class III |
| Status | terminated |
| Initiated | 2017-12-22 |
| Published | 2018-01-24 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Hetero Labs Unit Iii |
| Distribution | US |
Product
Simvastatin Tablets, USP, 40 mg, 1000-count bottle, Rx only, Manufactured for: Camber Pharmaceuticals, Inc., Piscataway, NJ 08854, Manufactured by: Hetero (trademark), Hetero Labs Limited, Jeedimetla, Hyderabad - 500 055, India, NDC 31722-513-10
Reason
Presence of foreign substance: metallic razor blade was found in one bottle.
Identifiers
| ndc | 31722-510-30 |
|---|---|
| ndc | 31722-510-01 |
| ndc | 31722-510-10 |
| ndc | 31722-510-90 |
| ndc | 31722-511-30 |
| ndc | 31722-511-01 |
| ndc | 31722-511-10 |
| ndc | 31722-511-90 |
| ndc | 31722-512-30 |
| ndc | 31722-512-01 |
| ndc | 31722-512-10 |
| ndc | 31722-512-90 |
| ndc | 31722-513-30 |
| ndc | 31722-513-01 |
| ndc | 31722-513-10 |
| ndc | 31722-513-90 |
| ndc | 31722-514-30 |
| ndc | 31722-514-01 |
| ndc | 31722-514-05 |
| ndc | 31722-514-90 |
| code_info | Lot #: E171280, Exp 06/19 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0223-2018%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.